Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Lariat Peptide Inhibitors of the Transcription Factor ETV6

EF 2015-16

Résumé
Specifically inhibiting protein-DNA interactions with small molecules is a holy grail of drug development. A promising solution to this difficult task is to use peptides as inhibitors, which have protein-like features and are able to strongly bind proteins. Due to proteolytic degradation and poor cellular uptake, linear peptides are not an attractive option. However unlike their linear counterparts, cyclic peptides are less sensitive to proteolysis than their linear counterparts, and may diffuse across cellular membranes. In collaboration, we have developed a split-intein system to biosynthetically generate lactone-cyclized lariat peptides. When used in combination with yeast display to screen vast peptide libraries, our collaborators identified several candidate lariat peptides that appear to bind to and inhibit the DNA-binding ETS domain of ETV6. This model system is a member of the ETS family of eukaryotic transcription factors and a known oncogene. My immediate goals are to characterize the in vitro interactions of these bacterially-expressed lariat peptides with several ETS domains using biophysical methods including calorimetry and NMR spectroscopy. This will enable me to accurately determine the affinity and specificity of these peptides for ETS family members, and to identify how the peptides prevent DNA binding. This knowledge will enable me to carry out the designed evolution of lariat peptides to better target these transcription factors. Such peptides that inhibit protein-DNA interactions may serve as lead compounds for the development of cyclic peptide therapeutics that treat diseases of gene expression, including cancers linked to ETS factors.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
350054
Name
Scheu Karlton
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Lariat Peptide Inhibitors of the Transcription Factor ETV6
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cyclic Peptides; Dna Binding Inhibition; Dna-Protein Interface; Ets; Nmr; Protein-Protein Interractions; Transcription Factors
Abstract
Specifically inhibiting protein-DNA interactions with small molecules is a holy grail of drug development. A promising solution to this difficult task is to use peptides as inhibitors, which have protein-like features and are able to strongly bind proteins. Due to proteolytic degradation and poor cellular uptake, linear peptides are not an attractive option. However unlike their linear counterparts, cyclic peptides are less sensitive to proteolysis than their linear counterparts, and may diffuse across cellular membranes. In collaboration, we have developed a split-intein system to biosynthetically generate lactone-cyclized lariat peptides. When used in combination with yeast display to screen vast peptide libraries, our collaborators identified several candidate lariat peptides that appear to bind to and inhibit the DNA-binding ETS domain of ETV6. This model system is a member of the ETS family of eukaryotic transcription factors and a known oncogene. My immediate goals are to characterize the in vitro interactions of these bacterially-expressed lariat peptides with several ETS domains using biophysical methods including calorimetry and NMR spectroscopy. This will enable me to accurately determine the affinity and specificity of these peptides for ETS family members, and to identify how the peptides prevent DNA binding. This knowledge will enable me to carry out the designed evolution of lariat peptides to better target these transcription factors. Such peptides that inhibit protein-DNA interactions may serve as lead compounds for the development of cyclic peptide therapeutics that treat diseases of gene expression, including cancers linked to ETS factors.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Scheu, Karlton
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~